Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 225-730-9 | CAS number: 5036-48-6
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
N-(3-Aminopropyl)-imidazole is considered to be favourable for GIT absorption and to be systemically available. However, there are no indications for a potential to accumulate.
Key value for chemical safety assessment
Additional information
There are no studies available for the determination of toxicokinetics or dermal absorption.
N-(3-Aminopropyl)-imidazole, CAS 5036-48-6 (API) is a liquid substance with a molecular weight of 125.1 g/mol and a vapour pressure of 0.0012 hPa at 20°C. It is miscible with water at room temperature in any ratio and the log Pow is -0.57 at 23°C and pH 10.8.
Because of its physico-chemical properties (log Pow between -1 and 4 and a MW < 500 g/mol), API is favourable for GIT absorption. Due to its low VP of 0.0012 hPa, the saturated vapour concentration is about 0.006 mg/L and exposure by vapour is rather unlikely. There is no information concerning dermal penetration, but the substance is corrosive to the skin (1986: RL2).
Evidence for systemic availability of API comes from a repeated dose toxicity study in rats: In the oral 28-day study (1999; RL1), transient mild hypoproteinemia (significant reduced total protein and albumin levels only in males) was found in the high dose group of 1000 mg/kg bw/d. In the oral 90 -d study (2019; RL1) incrased liver weights in the high dose females (1000 mg/kg bw/d) as well as some changes in clinical chemistry in both sexes indicated a changed liver cell metabolism. However, the local irritation of the mucosa of the stomach/forestomach in the high dose group was considered to be the main effect of API after 90 days of administration.
In the acute oral study, rats showed clinical signs and the LD50 was 1780 mg/kg bw (1986; RL2). The effects observed in the rats, which died (dark red stomach, small and large intestines with bloody contents), are considered to be caused mainly by the corrosivity of the substance (GHS EU: Skin Corr. Cat. 1B) and are therefore no indicators of specific organ toxicity after single exposure.
Studies on mutagenicity in vitro (Ames-Test, in vitro CA, HPRT) were negative, i.e. there is no indication of a reactivity of API or its metabolites under the test conditions.
The results of the RDT studies in rats do not indicate a potential of API for accumulation. Therefore, excretion via the urine is most likely. This is supported by the log Pow value of -0.57.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
